专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20030003564A1 Methods and compositions for modulating ubiquitin dependent proteolysis 审中-公开
公开(公告)号：US20030003564A1
公开(公告)日：2003-01-02
申请号：US10060019
申请日：2002-01-29
申请人： Mount Sinai Hospital Corporation
发明人： Mike Tyers , Andrew Willems
IPC分类号： A61K038/48 , C12N009/64
CPC分类号： C07K14/395 , A61K38/00 , C07K14/4738
摘要： The invention relates to methods and compositions for modulating ubiquitin dependent proteolysis.

2. 发明申请

US20020111695A1 Reconstituted mineralized cartilage tissue 审中-公开
标题翻译：重建矿化软骨组织
公开(公告)号：US20020111695A1
公开(公告)日：2002-08-15
申请号：US10121738
申请日：2002-04-12
申请人： Mount Sinai Hospital Corporation
发明人： Rita Kandel
IPC分类号： A61F002/28
CPC分类号： C12N5/0068 , A61K35/12 , A61K48/00 , A61L27/3608 , A61L27/3633 , A61L27/365 , A61L27/3654 , A61L27/3817 , A61L27/3847 , A61L27/3852 , A61L27/3895 , A61L2430/06 , C12N5/0655 , C12N2500/42 , C12N2533/90
摘要： A biological material comprising a continuous layer of cartilaginous tissue reconstituted in vitro which contains components associated with cartilage mineralization. The biological material may be cultured with a mineralizing agent to form a mineralized biological material. The mineralized biological material is characterized by having a biochemical composition and physiological organization substantially similar to the deep and contiguous calcified cartilage zones of articular cartilage found in animals in vivo. Methods for preparing the biological materials and methods of using the biological materials are described.
摘要翻译：一种生物材料，其包含体外重组的软骨组织的连续层，其含有与软骨矿化相关的成分。生物材料可以与矿化剂一起培养以形成矿化生物材料。矿化生物材料的特征在于具有与动物体内发现的关节软骨的深层和连续钙化软骨区基本相似的生化组成和生理组织。描述了制备生物材料的方法和使用生物材料的方法。

3. 发明申请

US20020110833A1 Methods to diagnose a required regulation of trophoblast invasion 失效
公开(公告)号：US20020110833A1
公开(公告)日：2002-08-15
申请号：US10028158
申请日：2001-12-20
申请人： Mount Sinai Hospital Corporation
发明人： Isabella Caniggia , Martin Post , Stephen Lye
IPC分类号： G01N033/53 , A61K039/395 , A61K038/17
CPC分类号： C12Q1/6883 , C12Q2600/158 , G01N33/6863 , G01N33/689 , G01N33/74 , G01N2333/495 , G01N2333/71 , G01N2800/36 , G01N2800/368
摘要： Methods are provided for the diagnosis and treatment of patients with increased risk of preeclampsia. The methods involve measuring levels of TGF-null3, receptors of cytokines of the TGnull family, or HIF-1null.

4. 发明申请

US20020172984A1 Oligomerized receptors which affect pathways regulated by transmembrane ligands for elk-related receptor tyrosine kinases 审中-公开
标题翻译：影响通过跨膜配体调节的麋鹿相关受体酪氨酸激酶的寡聚受体
公开(公告)号：US20020172984A1
公开(公告)日：2002-11-21
申请号：US10138787
申请日：2002-05-03
申请人： Mount Sinai Hospital Corporation
发明人： Sacha Holland , Geraldine Mbamalu , Tony Pawson
IPC分类号： G01N033/567 , A61K038/51
CPC分类号： C12N9/1205 , A61K38/00 , C07K14/4702 , C07K14/705 , C07K2319/00 , C12Q1/6897
摘要： A method of modulating the biological activity of a transmembrane ligand for an Elk-related receptor tyrosine kinase in a cell expressing the transmembrane ligand, comprising forming a complex between a purified and isolated oligomerized Elk-related receptor tyrosine kinase, or an isoform or an extracellular domain of the kinase, and a transmembrane ligand expressed on the cell, thereby affecting a pathway in the cell which is regulated by the transmembrane ligand.
摘要翻译：一种调节表达跨膜配体的细胞中Elk相关受体酪氨酸激酶的跨膜配体的生物学活性的方法，包括在纯化和分离的寡聚化的Elk相关受体酪氨酸激酶或同种型或细胞外激酶的结构域和在细胞上表达的跨膜配体，从而影响由跨膜配体调节的细胞中的途径。

5. 发明申请

US20030106076A1 Methods for identifying genes expressed in selected lineages, and a novel genes identified using the methods 审中-公开
标题翻译：用于鉴定选择谱系中表达的基因的方法，以及使用该方法鉴定的新基因
公开(公告)号：US20030106076A1
公开(公告)日：2003-06-05
申请号：US10194746
申请日：2002-07-12
申请人： Mount Sinai Hospital Corporation
发明人： William Stanford , Georgina Caruana , Michihiro Hidaka , Alan Bernstein
IPC分类号： A01K067/00 , C12Q001/68 , C07H021/04 , C12P021/02 , C12N005/06
CPC分类号： C07K14/47 , C12Q1/68 , C12Q1/6897
摘要： The invention relates to vectors, compositions, and methods for identifying genes primarily expressed in selected lineages. The invention also relates to novel genes primarily expressed in selected lineages, proteins encoded by the novel genes and truncations, analogs, homologs, and isoforms of the proteins and uses of the proteins and genes.
摘要翻译：本发明涉及用于鉴定主要在选择谱系中表达的基因的载体，组合物和方法。本发明还涉及主要在选择的谱系中表达的新基因，由新基因编码的蛋白质和蛋白质的截短，类似物，同系物和同种型以及蛋白质和基因的用途。

6. 发明申请

WO1997047296A2 COMPOSITIONS COMPRISING VANADIUM COMPOUNDS FOR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS AND ARTHROPATHIES 审中-公开
标题翻译：包含VANADIUM化合物用于治疗增生性疾病和ARTHROPATHIES的组合物
公开(公告)号：WO1997047296A2
公开(公告)日：1997-12-18
申请号：PCT/CA1997000405
申请日：1997-06-12
申请人： MOUNT SINAI HOSPITAL CORPORATION , CRUZ, Tony
发明人： MOUNT SINAI HOSPITAL CORPORATION
IPC分类号： A61K31/28
CPC分类号： A61K33/24 , A61K31/28 , A61K31/555 , A61K45/06 , A61K31/195 , A61K2300/00
摘要： The present invention relates to the use of vanadium compounds as antiproliferative and anti-metastatic agents, to treat arthropathy and drug resistant tumors in animals; to compositions containing vanadium compounds adapted for such uses; to methods for the treatment of proliferative disorders, to methods of reducing the ability of a tumor to metastasize, to methods for treating drug resistant tumors and to methods for treating arthropathies, such as arthritis.
摘要翻译：本发明涉及钒化合物作为抗增殖和抗转移剂的用途，用于治疗动物中的关节病和耐药性肿瘤; 包含适用于这种用途的含钒化合物的组合物; 用于治疗增殖性疾病的方法，降低肿瘤转移能力的方法，治疗耐药性肿瘤的方法和治疗关节病如关节炎的方法。

7. 发明申请

WO1997014966A1 METHOD OF ACTIVATING A NOVEL LIGAND REGULATORY PATHWAY 审中-公开
标题翻译：激活新的配对管制路径的方法
公开(公告)号：WO1997014966A1
公开(公告)日：1997-04-24
申请号：PCT/CA1996000679
申请日：1996-10-10
申请人： MOUNT SINAI HOSPITAL CORPORATION
发明人： MOUNT SINAI HOSPITAL CORPORATION , PAWSON, Anthony , HENKEMEYER, Mark
IPC分类号： G01N33/68
CPC分类号： G01N33/68 , A61K38/19 , G01N33/6896 , G01N2333/705 , G01N2333/912
摘要： A novel ligand regulatory pathway is disclosed and methods of activating the novel pathway in a cell expressing a ligand for an Eph subfamily receptor tyrosine kinase protein. Methods are provided for identifying substances capable of activating the ligand regulatory pathway. Therapeutic methods for affecting neuronal development and regeneration and pharmaceutical compositions using the substances and Eph subfamily receptor tyrosine kinase proteins are also described.
摘要翻译：公开了一种新的配体调节途径以及在表达Eph亚家族受体酪氨酸激酶蛋白质配体的细胞中激活新途径的方法。提供了用于鉴定能够激活配体调节途径的物质的方法。还描述了影响神经元发育和再生的治疗方法以及使用该物质和Eph亚家族受体酪氨酸激酶蛋白的药物组合物。

8. 发明申请

WO1994004694A1 ENDOTHELIAL LINEAGE SPECIFIC TRANSCRIPTIONAL REGULATORY ELEMENT FROM TEK 审中-公开
标题翻译：内皮细胞特异性转录调节元件
公开(公告)号：WO1994004694A1
公开(公告)日：1994-03-03
申请号：PCT/CA1993000352
申请日：1993-08-25
申请人： MOUNT SINAI HOSPITAL CORPORATION , BREITMAN, Martin, L. , DUMONT, Daniel , GRADWOHL, Gerard, G.
发明人： MOUNT SINAI HOSPITAL CORPORATION
IPC分类号： C12N15/85
CPC分类号： A01K67/0275 , A01K2217/05 , A61K48/00 , C12N9/1205 , C12N15/85
摘要： The present invention therefore provides a transcriptional regulatory element which is capable of directing expression of a gene specifically in cells of the endothelial lineage. Preferably, the transcriptional regulatory element comprises the initiation codon and the untranslated sequences of tek, a protein tyrosine kinase expressed during murine cardiogenesis and homologues thereof including the human tek gene. The transcriptional regulatory element may be used to target expression of a gene in cells of the endothelial lineage.
摘要翻译：因此，本发明提供了一种转录调控元件，其能够将基因特异性表达在内皮谱系的细胞中。优选地，转录调节元件包括tek的起始密码子和非翻译序列，在小鼠心脏发生期间表达的蛋白质酪氨酸激酶及其包括人类tek基因的同源物。转录调节元件可用于靶向内皮细胞系细胞中基因的表达。

9. 发明申请

WO1998001548A1 OLIGOMERIZED RECEPTORS WHICH AFFECT PATHWAYS REGULATED BY TRANSMEMBRANE LIGANDS FOR ELK-RELATED RECEPTOR TYROSINE KINASES 审中-公开
标题翻译：影响与ELK相关的受体类型的激素转运蛋白配体调节途径的受体受体
公开(公告)号：WO1998001548A1
公开(公告)日：1998-01-15
申请号：PCT/CA1997000473
申请日：1997-07-04
申请人： MOUNT SINAI HOSPITAL CORPORATION , HOLLAND, Sacha , MBAMALU, Geraldine , PAWSON, Tony
发明人： MOUNT SINAI HOSPITAL CORPORATION
IPC分类号： C12N15/12
CPC分类号： C12N9/1205 , A61K38/00 , C07K14/4702 , C07K14/705 , C07K2319/00 , C12Q1/6897
摘要： A method of modulating the biological activity of a transmembrane ligand for an Elk-related receptor tyrosine kinase in a cell expressing the transmembrane ligand, comprising forming a complex between a purified and isolated oligomerized Elk-related receptor tyrosine kinase, or an isoform or an extracellular domain of the kinase, and a transmembrane ligand expressed on the cell, thereby affecting a pathway in the cell which is regulated by the transmembrane ligand.
摘要翻译：调节表达跨膜配体的细胞中与Elk相关的受体酪氨酸激酶的跨膜配体的生物学活性的方法，包括在纯化和分离的寡聚化的Elk相关受体酪氨酸激酶或同种型或细胞外激酶的结构域和在细胞上表达的跨膜配体，从而影响由跨膜配体调节的细胞中的途径。

10. 发明申请

WO1997015318A1 PEPTIDE INHIBITORS OF A PHOSPHOTYROSINE-BINDING DOMAIN CONTAINING PROTEIN 审中-公开
标题翻译：含有蛋白质结合蛋白的蛋白质的肽抑制剂
公开(公告)号：WO1997015318A1
公开(公告)日：1997-05-01
申请号：PCT/US1996017080
申请日：1996-10-24
申请人： MOUNT SINAI HOSPITAL CORPORATION , ASAHI CHEMICAL INDUSTRY CO., LTD. , VAN DER GEER, Peter , WILEY, Sandra , GISH, Gerald , PAWSON, Tony , TOMA, Kazunori
发明人： MOUNT SINAI HOSPITAL CORPORATION , ASAHI CHEMICAL INDUSTRY CO., LTD.
IPC分类号： A61K38/08
CPC分类号： C07K14/715 , A61K38/00 , C07K14/71
摘要： A peptide of the formula (I): X -A -A -X -Asn-X -X -P.Tyr-X -X -X X , wherein X represents Lys, Arg, His, Ser, Thr, Tyr, Asn, Leu, Val or Glu, A represents Trp, Leu, Ala, Ser, Ile, Glu, Met, Gly, Cys, Phe, Pro or Val, and A represents Ala, Val, Leu, Ile, Ser, Met, Phe, Gly, Cys, Trp or Pro, X represents Glu, Asn, Tyr, Thr, Ser, Asp or Ile, X represents Pro, Met, Trp, Phe, Ala, Lys, Val, Leu, Ile, Gly or Cys, X represents Leu, Ala, Glu, Gln, Asp, Asn, Tyr, Thr or Ser, X represents Phe, Trp, Pro, Leu, Ala, Val, Ile, Gly, Cys, Met, Arg or Ser, X represents Ser, Thr, Tyr, Asn, Glu, Met, Ala, Leu, Val or Gly, X represents Asp, Glu, Ala, Val, Leu, Ile, Gly, Cys, Phe, Trp, Met, Pro, Ser or Asn and X which may be present or absent represents Phe, Trp, Pro, Leu, Ala, Val, Ile, Gly, Cys, Met, Asp, Ser or Arg which interferes with the interaction of a PTB domain containing protein with a PTB domain binding site, and truncations and analogues of the peptide.
摘要翻译：式（I）的肽：X 1 -A 1 -A 2 -X 2 -As n -X 3 -X 4 -P.Tyr-X 5 - X 6 -X X 7-，其中X 1表示Lys，Arg，His，Ser，Thr，Tyr，Asn，Leu，Val或Glu，A 1表示Trp，Leu， Ala，Ser，Ile，Glu，Met，Gly，Cys，Phe，Pro或Val，A 2代表Ala，Val，Leu，Ile，Ser，Met，Phe，Gly，Cys，Trp或Pro， 2表示Glu，Asn，Tyr，Thr，Ser，Asp或Ile，X 3表示Pro，Met，Trp，Phe，Ala，Lys，Val，Leu，Ile，Gly或Cys，X 4表示Leu ，Ala，Glu，Gln，Asp，Asn，Tyr，Thr或Ser，X 5表示Phe，Trp，Pro，Leu，Ala，Val，Ile，Gly，Cys，Met，Arg或Ser，X 6，表示Ser，Thr，Tyr，Asn，Glu，Met，Ala，Leu，Val或Gly，X 7表示Asp，Glu，Ala，Val，Leu，Ile，Gly，Cys，Phe，Trp，Met，Pro，可能存在或不存在的Ser或Asn和X 8表示干扰与包含的PTB结构域相互作用的Phe，Trp，Pro，Leu，Ala，Val，Ile，Gly，Cys，Met，Asp，Ser或Arg 具有PTB结构域结合位点的蛋白质，以及t的截短和类似物他的肽。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式